The revolutionary Alpha DaRT technology uses Alpha radiation to treat cancer.

​

AlphaDaRT seeds release a high-energy dose over a range of several millimeters enabling a focal alpha-radiation treatment that spares the surrounding healthy tissue.

​

DaRT (Diffusion Alpha-emitter Radiation Therapy) treats solid tumors with interstitial radioactive seeds that continuously release short-lived alpha-half-life atoms into the tumor.

​

AlphaDaRT enables highly effective and compliant radiation treatment for solid tumors. Inserted directly into the tumor, the AlphaDaRT seed delivers a high-energy dose over a range of a few millimeters allowing for treatment that spares the surrounding healthy tissue.

​

​AlphaTau Medical is currently conducting clinical trials on various indications. In addition to the ongoing trial on squamous cell carcinoma of the head, neck and skin, the company is collaborating with leading cancer researchers on further protocols such as prostate cancer, breast cancer, gynecological cancer, cancer colorectal and pancreatic cancer.

​

On last 2020, AlphaTau has announced the closing of a $26 million Series B financing round from investors, including Shavit Capital, Medison Ventures, and OurCrowd. The private investment business primarily from Israel and North America.